insert an image 968px x 220px


Gentronix achieves prospective membership of the UK GLP Compliance Monitoring Programme

Posted on July 25, 2014 by Chris Hughes


Gentronix Limited, the leading specialist genotoxicity company, is pleased to announce that on 22nd July 2014, it was notified by the UK MHRA that it has been successful in achieving Prospective Membership of the UK GLP Compliance Monitoring Programme. This means that, from 22nd July 2014, GLP compliance can be claimed for work conducted by Gentronix. The company is currently able to offer  the GLP assays defined in the “OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects” tests  471: Bacterial Reverse Mutation and 487: In Vitro Mammalian Cell Micronucleus Tests. An implementation inspection by the UK MHRA…

Read the rest of this news item

Gentronix now offers non-GLP Ames Bacterial Reverse Mutation Screening Assay

Posted on July 21, 2014 by Chris Hughes

Gentronix is now able to offer 5-strain full Ames screening that is compliant with OECD Guideline 471. Because formulation analysis and Quality Assurance are omitted, it is not GLP compliant. However it is performed under GLP principles by GLP experienced analysts.. A bacterial reverse mutation test (often simply referred to as an ‘Ames test’) is a core component of safety assessment testing batteries, e.g. ICH S2(R1), performed in amino acid-requiring strains of Salmonella typhimurium or Escherichia coli.  Point mutations, involving substitution, addition or deletion of one or a few DNA base pairs, are detected when they cause restoration of the…

Read the rest of this news item

Gentronix Scientists at EEMS

Posted on June 27, 2014 by Chris Hughes


Although not exhibiting, Gentronix CSO and founder Richard Walmsley, and Technical Manager Matt Tate will be attending the annual meeting of the European Environmental Mutagen Society in Lancaster UK, 6-10 July. Contact us to arrange a meeting. The conference website can be found here

Read the rest of this news item

Gentronix CSO and founder to present plenary lecture at International Medicinal Chemistry Meeting (RICT 2014)

Posted on May 12, 2014 by Chris Hughes

Gentronix CSO and Founder, Professor Richard Walmsley, has been invited to give a plenary lecture at the International Medicinal Chemistry Meeting,(RICT 2014), in Rouen, Normandy, France on Thursday 3rd July. The talk is entitled “Genotoxicity Screening can guide Lead Optimisation and Reduce Late Stage Attrition” Details of the conference can be found here

Read the rest of this news item